Pharming (PHAR) EV to EBITDA (2020 - 2026)
Powered by 
Analysis
Pharming (PHAR) EV to EBITDA (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 10 | Pharming | 794.84 Mn | 635.34 Mn | 141.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -226.55 |
| Mar 31, 2026 | -179.18 |
| Dec 31, 2025 | 165.32 Mn |
| Sep 30, 2025 | 51.92 |
| Mar 31, 2025 | -59.23 |
| Dec 31, 2024 | -33.76 |
| Sep 30, 2024 | 93.14 |
| Jun 30, 2024 | -20.58 |
| Mar 31, 2024 | -32.24 |
| Dec 31, 2023 | 503.28 |
| Sep 30, 2023 | 288.61 |
| Jun 30, 2023 | 107.98 |
| Mar 31, 2023 | -51.31 |
| Dec 31, 2022 | 18.19 |
| Sep 30, 2022 | 57.24 |
| Jun 30, 2022 | 21.24 |
| Mar 31, 2022 | 140.47 |
| Dec 31, 2021 | -39.62 |
| Sep 30, 2021 | -251.81 |
| Jun 30, 2021 | 48.68 |